Published July 2, 2012 by NY Times In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday. […]
The post GlaxoSmithKline (GSK) Agrees to Pay $3 Billion in Fraud Settlement to U.S. appeared first on .